Skin squamous cell carcinoma
Therapeutic area
Oncology
Rare disease
No
- Definition
- A carcinoma arising from the squamous cells of the epidermis. Skin squamous cell carcinoma is most commonly found on sun-exposed areas. The majority of the tumors are well-differentiated.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Skin squamous cell carcinoma
- Therapeutic area
- Oncology
- skin squamous cell carcinoma
- cutaneous squamous cell carcinoma
- epidermoid carcinoma of skin
- epidermoid carcinoma of the skin
- epidermoid skin carcinoma
- skin squamous cell cancer
- skin squamous cell carcinoma
- squamous cell carcinoma - skin
- squamous cell carcinoma of skin
- squamous cell carcinoma of the skin
- squamous cell skin carcinoma
- zone of skin squamous cell carcinoma
- CSCC
- Severity
- Severe
- Dermatology
- Oncology
- MONDO ID
- MONDO:0002529
- Parent condition
- MONDO:0002656
Related records
Broader conditions (19)
- Cancer
- Cancer or benign tumor
- Carcinoma
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Epithelial neoplasm
- Epithelial skin neoplasm
- Human disease
- Integumentary system cancer
- Integumentary system disorder
- Neoplasm
- Neoplastic disease or syndrome
- Skin cancer
- Skin carcinoma
- Skin disorder
- Skin neoplasm
- Squamous cell carcinoma
- Squamous cell neoplasm
Narrower conditions (10)
- Acantholytic squamous cell skin carcinoma
- Anal margin squamous cell carcinoma
- Bowen disease of the skin
- Clear cell squamous cell skin carcinoma
- Plantar verrucous skin carcinoma
- Pseudovascular skin squamous cell carcinoma
- Sarcomatoid squamous cell skin carcinoma
- Skin adenosquamous carcinoma
- Skin basaloid carcinoma
- Skin squamous cell carcinoma in situ
Trials (176)
- A Beta-only IL-2 ImmunoTherapY Study
- A First-in-Human Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of KUP-101A in Patients With Selected Advanced Solid Tumors
- A PD-1 Checkpoint Inhibitor (Cemiplimab) for High-Risk Localized, Locally Recurrent, or Regionally Advanced Skin Cancer
- A Phase 0 Window of Opportunity Trial of Intratumoral Seasonal Influenza Immunization in Cutaneous Squamous Cell Carcinoma (CSCC) Patients Awaiting Curative Excision
- A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers
- A Randomized Controlled Trial of Topical 5% Niacinamide for Skin Cancer Prevention in Transplant Recipients
- A Study of IDP-001 in Advanced or Metastatic Solid Tumors
- A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
- A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer
- A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers (Pegathor Skin 201)
- A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors
- A Study of Tolododekin Alfa (ANK-101) in Renal Allograft Recipients With High Risk Cutaneous Squamous Cell Carcinoma
- A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors
- A Study of VET3-TGI in Patients With Solid Tumors
- A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma
- A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer
- A Window of Opportunity Trial of Intratumoral Injection of Copaxone® in Patients With Percutaneously Accessible Tumors
- ACCEPTABILITY AND WRITING FREQUENCY OF ADVANCED DIRECTIVES IN ONCO-DERMATOLOGY PATIENTS
- Alpha Radiation Emitters Device for the Treatment of Squamous Cell Carcinoma (DaRT)
- An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors
Drugs in development (1)
- Avelumab Phase 2